Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China

Inclusion Criteria: Inclusion Criteria: * Patient diagnosed with macular edema due to RVO (either BRVO or CRVO, non-ischemic) * Retinal thickness ≥ 300 μm by SD-OCT in the central 1 mm macular subfield of the study eye at the Screening visit * BCVA score of 19 to 73 letters (approximately 20/400 to 20/40 Snellen equivalent) in the study eye measured by ETDRS method at Screening * \< 3 months of macular edema duration * Treatment-naive patients (ie, have not previously received any treatment for macular edema secondary to RVO) Exclusion Criteria: * Uncontrolled systemic disease * Presence of/history of any ocular condition other than macular edema that affects visual acuity (eg, cataract, severe macular ischemia, foveal atrophy, age-related macular degeneration, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass syndrome, prior macular detachment) * Any of the following ≤ 3 months before study entry or anticipated need within the coming 3 months: * Intraocular surgery * Laser photocoagulation * Intraocular injection * Periocular steroid injection * Vitrectomized eye * Aphakic eyes with ruptured posterior lens capsule or presence of an ACIOL, iris or transscleral fixated intraocular lens * History of marked IOP elevation in response to steroid treatment that (a) required IOP-lowering treatment, (b) resulted in a \>10 mm Hg increase in IOP from predose, or (c) resulted in IOP \>25 mm Hg * History of glaucoma or ocular hypertension (IOP \> 21 mm Hg), or optic nerve head change consistent with glaucoma damage, and/or glaucomatous visual field loss in the study eye (patients with a history of previous angle closure that has been successfully treated with either a laser or surgical peripheral iridotomy \[PI\] are allowed as long as the visual fields have been stable for \> 1 year prior to study entry and the patient has been and can be safely dilated). * Any active ocular infection (i.e., bacterial, viral, parasitic, or fungal) in either eye at the Screening visit * Female patients who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using a reliable means of contraception * Any condition that may interfere or preclude participation in the study * Use of systemic steroids (e.g., oral, intravenous, intramuscular, epidural, rectal, or extensive dermal) within 1 month prior to Baseline or anticipated use at any time during the study (inhaled, intranasal, and intra-articular/intrabursal corticosteroids are allowed) * Use of immunosuppressants, immunomodulators, antimetabolites, and/or alkylating agents within 3 months prior to Baseline or anticipated use at any time during the study * Use of warfarin or heparin within 2 weeks prior to Baseline or anticipated use within the study period * Known allergy, hypersensitivity or contraindication to the study medication, its components, fluorescein or povidone iodine * Current enrollment in another drug or device study within 30 days prior to Baseline